Analysts Set Pfizer Inc. (NYSE:PFE) PT at $31.92

Shares of Pfizer Inc. (NYSE:PFE) have received a consensus rating of “Moderate Buy” from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, five have issued a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $31.92.

A number of brokerages have recently commented on PFE. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently bought and sold shares of the company. Swedbank AB lifted its stake in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after buying an additional 37,636 shares during the period. United Bank lifted its stake in shares of Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 1,277 shares during the period. Thrivent Financial for Lutherans lifted its stake in shares of Pfizer by 14.5% during the third quarter. Thrivent Financial for Lutherans now owns 846,582 shares of the biopharmaceutical company’s stock worth $24,500,000 after buying an additional 107,346 shares during the period. Meeder Advisory Services Inc. lifted its stake in shares of Pfizer by 2.5% during the third quarter. Meeder Advisory Services Inc. now owns 61,784 shares of the biopharmaceutical company’s stock worth $1,788,000 after buying an additional 1,503 shares during the period. Finally, Joseph Group Capital Management lifted its stake in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.1 %

Shares of NYSE PFE opened at $26.20 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $148.61 billion, a P/E ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a 50-day simple moving average of $26.17 and a two-hundred day simple moving average of $27.05.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 earnings per share. Research analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.